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Aims Cardiomyopathies are a heterogeneous group of disorders associated with premature death due to ventricular arrhyth-
mia or heart failure. The purpose of this study was to examine the characteristics of patients enrolled in the pilot phase
of the EURObservational Research Programme (EORP) cardiomyopathy registry.
Methods
and results
Between 1 December 2012 and 30 November 2013, four cardiomyopathy phenotypes were studied: hypertrophic car-
diomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and
restrictive cardiomyopathy (RCM). Twenty-seven centres in 12 countries participated; 1115 patients were enrolled.
The commonest cardiomyopathy was HCM (n ¼ 681), followed by DCM (n ¼ 346), ARVC (n ¼ 59), and RCM
(n ¼ 29); 423 patients (46.4% of those reported) had familial disease; and 56 (5.0%) had rare disease phenocopies. Me-
dian age at enrolment and diagnosis was 54 [interquartile range (IQR), 42–64] and 46 years (IQR, 32–58), respectively;
fewer patients with ARVC and more with RCM were diagnosed in the upper age quartile (P , 0.0001). There was a
male predominance for all cardiomyopathies except RCM (P ¼ 0.0023). Most patients were in New York Heart Asso-
ciation functional class I (n ¼ 813) at enrolment; 139 (12.5%) reported syncope, most frequently in ARVC (P ¼ 0.0009).
Five hundred and seven (45.5%) patients underwent cardiac magnetic resonance imaging, 117 (10.6%) endomyocardial
biopsy, and 462 (41.4%) genetic testing with a causative mutation reported in 236 individuals (51.1%). 1026 patients
(92.0%) were receiving drug therapy; 316 (28.3%) had received an implantable cardioverter defibrillator (highest pro-
portion in ARVC, P , 0.0001).
Conclusion This pilot study shows that services for patients with cardiomyopathy are complex, requiring access to a large range of
invasive and non-invasive investigations and involvement of multidisciplinary teams. Treatment regimens are equally
multifaceted and show that patients are likely to need long-term follow-up in close liaison with expert centres.
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Cardiomyopathies are a heterogeneous group of disorders charac-
terized by structural and functional abnormalities of the myocar-
dium that are not explained solely by coronary artery disease or
abnormal loading conditions.1 Individually, the various subtypes of
cardiomyopathies are relatively uncommon, but collectively they re-
present a major health burden for the European population.2– 9 All
cardiomyopathies can cause premature death from arrhythmia and
progressive heart failure.2,4– 9
To date, most information about the presentation and natural his-
tory of individual disorders has come from cohort studies in a few
centres in Europe and the USA. The European Society of Cardiology
(ESC) launched the EURObservational Research Programme
(EORP) in 2009 with the aim of improving the understanding of
medical practice by collecting observational data using robust meth-
odological procedures.10 The programme is based on networks of
volunteer centres appointed by ESC constituent bodies, and the
cardiomyopathy registry is a prospective, multicentre, observational
study of patients presenting to referral cardiomyopathy centres
in European countries, conducted by the ESC Working Group
on Myocardial and Pericardial Disease (http://www.escardio.org/The-
ESC/Communities/Working-Groups/Working-Group-on-Myocardial-
and-Pericardial-Diseases/Myocardial-and-Pericardial-Disease).
The primary aim of the cardiomyopathy registry is to collect data
on the epidemiology and outcomes of patients seen across a range
of centres in Europe in order to provide information that can be
used to improve clinical management and service provision. This
first report summarizes the pilot phase of the survey, conducted
in advance of the long-term project (http://www.escardio.org/
Guidelines-&-Education/Trials-and-Registries/EURObservational-
Research-Programme) to test feasibility of recruitment and to refine
data collection procedures.
Methods
Registry design and methodology
Participating centres in each country were selected using pre-specified
inclusion and exclusion criteria (Supplementary material online, File S1).
Briefly, all participating centres in the pilot phase were required to have
dedicated cardiomyopathy clinics staffed by experienced medical and
nursing teams and access to facilities for genetic testing of the main
genes implicated in cardiomyopathy with demonstrable experience in
the interpretation of the results.
The primary aims of the registry were as follows:
(i) to describe the demographic, clinical, and genetic characteristics of
patients with cardiomyopathy evaluated in referral centres across
Europe;
(ii) to record the current standards for diagnostic workup and clinical
follow-up of patients and families with cardiomyopathy;
(iii) to describe the therapeutic approaches currently employed for pa-
tients with different forms of cardiomyopathy across Europe;
(iv) to determine the proportion of patients with potentially inherit-
able disorders that is offered genetic counselling and testing;
(v) to determine the genetic profile of patients with familial forms of
cardiomyopathy;
(vi) to report the long-term outcomes including the benefits and com-
plications of treatments.
In this article, we report an overview of the first four aims in anticipation of
further detailed studies examining specific components of the database.
Patient population
For the purposes of this registry, cardiomyopathies were defined as myo-
cardial disorders in which the heart muscle is structurally and functionally
abnormal, in the absence of coronary artery disease, hypertension, valve
disease, and congenital heart disease sufficient to cause the observed
myocardial abnormality.1 Four major phenotypes of cardiomyopathies
were eligible for inclusion in the pilot: hypertrophic cardiomyopathy
(HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular
cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM). Left
ventricular non-compaction (LVNC) was reported as a clinical feature
in each of the four major cardiomyopathy subtypes but not in isolation.
Genetic and non-genetic forms of cardiomyopathy were eligible for inclu-
sion. Paediatric patients were also excluded from the pilot phase.
Inclusion criteria
This study was formulated in compliance with the principles of the dec-
laration of Helsinki, October 2000. Each participating centre was asked
to enter up to 40 consecutively assessed patients over a 12-month per-
iod. Informed consent was obtained from all participants before any in-
terviews or investigations were performed. All drug treatments and
diagnostic or therapeutic procedures were left to the discretion of
the attending physician. Individual investigators examined medical re-
cords to confirm that patients met the following inclusion criteria:
(i) age .18 years;
(ii) willing and able to give informed consent;
(iii) ability (in the investigators’ opinion) to comply with all study
requirements;
(iv) a documented cardiomyopathy fulfilling standard diagnostic cri-
teria (Supplementary material online, File S2) for probands or for
relatives according to modified criteria where applicable. Relatives
who fulfilled diagnostic criteria were eligible for recruitment as
long as they were seen prospectively as part of a consecutive popu-
lation with cardiomyopathy.
Patients who were unable to give informed consent were excluded
from the study.
Statistical analysis
Univariable analysis was applied to both continuous and categorical
variables. Continuous variables were reported as mean+SD and/or as me-
dian and interquartile range (IQR) when appropriate. Among-group com-
parisons were made using a non-parametric test (Kruskal–Wallis test).
Categorical variables were reported as percentages. Among-group com-
parisons were made using a x2 test or a Fisher’s exact test if any expected
cell count was less than five. A two-sided P-value of less than 0.05 was con-
sidered as statistically significant. All analyses were performed using SAS
statistical software version 9.4 (SAS Institute Inc., Cary, NC, USA).
This registry was conceived by the Working Group on Myocardial
and Pericardial Disease of the ESC, conducted by an Executive Commit-
tee, and managed by the EORP Department of the ESC.
Results
Data collection
Data collection for the pilot phase of the cardiomyopathy registry
began on 1 December 2012. Recruitment was complete by
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30 November 2013. One-year follow-up of patients enrolled in the
study ended on 1 December 2014.
Geographical distribution and number of
patients enrolled
Twenty-seven centres in 12 European countries participated in the
pilot survey (Figure 1); the total number of patients recruited was
1115. More than 50% of the patients came from one of the four
countries (France, Italy, Spain, and the UK). The majority of the pa-
tients enrolled were follow-ups rather than new referrals (876
follow-up, 216 new, 23 unknown), although the proportion varied
for individual centres (median new-to-follow-up ratio 24.7%, range
5.5–84.0).
Aetiology
The commonest cardiomyopathy recorded was HCM (n ¼ 681,
61.1%), followed, in the descending order, by DCM (n ¼ 346,
31.0%), ARVC (n ¼ 59, 5.3%), and RCM (n ¼ 29, 2.6%). Data on
LVNC were reported in 1086 of 1115 patients; of these, 35
(3.2%) had LVNC; the associated phenotype most commonly
reported in patients with LVNC was DCM (n ¼ 20/340, 5.9%)
followed by HCM (n ¼ 13/659, 2.0%) and ARVC (n ¼ 2/58, 3.5%).
A total of 56 (5.0%) patients were reported to have rare disease
phenocopies (Table 1). The most common was amyloidosis, which
was reported only in patients with HCM and RCM. Twenty-four of
these patients came from two centres (France and Italy).
A history of familial disease was recorded in 423 patients (46.4%
of those reported). This proportion was greatest for HCM and
ARVC and least for DCM and RCM (Table 2). The range for individ-
ual participating countries is shown in Figure 2. Four hundred and
sixty-two patients (41.4%) underwent genetic testing with a causa-
tive mutation reported in 236 individuals (51.1%).
Age and sex
The characteristics of the patient cohort are summarized in Table 2.
The median age at enrolment for the entire cohort was 54 years
(IQR, 42–64). The overall median age at diagnosis was 46 years
(IQR 32–58). For the cohort as a whole, there was an age-related
trend in the age at diagnosis, but there were significant differences
between cardiomyopathies with fewer patients with ARVC and
more with RCM diagnosed in the upper age quartile (P , 0.0001)
(Figure 3A and B). There was a male predominance for all cardio-
myopathy subtypes except RCM in which more women were re-
corded (P ¼ 0.0023) (Table 2).
Reason for diagnosis
The commonest reason for diagnosis in the cohort as a whole was
symptomatic presentation (56.1%), followed by incidental diagnosis
and family screening (17.2 and 15.1%, respectively). Symptomatic
presentation was more common in patients with RCM and DCM,
compared with HCM and ARVC [HCM 318 (46.7%), DCM 245
(70.8%), RCM 27 (93.1%), and ARVC 35 (59.3%)] (P ≤ 0.0001).
Diagnosis through family screening was more common in HCM
and ARVC than in DCM and RCM (P ≤ 0.0001).
Figure 1 Pie chart showing the proportion of patients recruited in the pilot registry (n ¼ 1115) enrolled in each participating country.










Most patients were in New York Heart Association (NYHA)
functional classes I and II (n ¼ 813, 72.9%) at enrolment (Table 2).
Patients with ARVC were youngest and those with RCM oldest
with respect to age at first symptoms [HCM 42.7+ 18.7 years,
44 (30–56); DCM 45.8+ 16.6 years, 47 (38–57); ARVC 36.4+
16.5 years, 39 (22–51); and RCM 54.2+ 21.2 years, 59 (36–72),
P , 0.0001].
Suspected arrhythmic/cardiogenic syncope was reported in 139
(12.5%) patients (greatest proportion in patients with ARVC,
Table 2) (P ¼ 0.0009). Patients with DCM were the oldest at last
syncope [50.2+ 18.6 years, 52 (47–63)] and those with ARVC
the youngest [35.2+ 15.6 years, 32 (21–43)] (P ¼ 0.0158).
Family history of sudden cardiac death
Two hundred and forty-six (22.1%) of all patients had a family his-
tory of sudden cardiac death (Table 2). This was most prevalent
in patients with ARVC followed by HCM, DCM, and RCM (P ¼
0.0003). The percentage of reported deaths among relatives aged
,45 years was greatest in value, although not statistically significant
in patients with ARVC (n ¼ 13, 65.0%) compared with other
groups.
Use of specialized diagnostic tests
The utilization of cardiac investigations is summarized in Table 3. The
majority of patients had an ECG or echocardiogram performed.
Ambulatory ECG monitoring and exercise testing were performed
Figure 2 Proportion of patients in each cardiomyopathy subtype with a family history of cardiomyopathy in each participating country.
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Table 1 Reported rare disease phenocopies in relation to cardiomyopathy subtypea
Diagnosis Total cohort HCM (n 5 681) DCM (n 5 346) RCM (n 5 29)
Mitochondrial disease, n (%) 5/1115 (0.4) 3/681 (0.4) 2/346 (0.6) 0 (0)
Danon disease, n (%) 4/1115 (0.4) 3/681 (0.4) 0 (0) 1/29 (3.5)
Friedreich’s ataxia, n (%) 2/1115 (0.2) 1/681 (0.1) 1/346 (0.3) 0 (0)
LEOPARD syndrome, n (%) 1/1115 (0.1) 1/681 (0.1) 0 (0) 0 (0)
Noonan syndrome, n (%) 1/1115 (0.1) 1/681 (0.1) 0 (0) 0 (0)
Anderson–Fabry disease, n (%) 12/1115 (1.1) 12/681 (1.8) 0 (0) 0 (0)
Amyloidosis, n (%) 31/1115 (2.8) 15/681 (2.2) 0 (0) 16/29 (55.2)
Total, n (%)b 56/1115 (5.0) 36/681 (5.3) 3/346 (0.9) 17/29 (58.6)
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LEOPARD, lentigines, electrocardiographic
abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities of the genitalia, retardation of growth, deafness.
aNo phenocopies were reported in ARVC.
bNo patient presented with more than one phenocopy.
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in 847 (76.0%) of the total cohort, with the highest proportion seen
in patients with HCM and ARVC. Patients with ARVC had the great-
est use of cardiac magnetic resonance imaging (n ¼ 37, 62.7%). Inva-
sive electrophysiology study was reported in 77 (7%) patients in the
entire cohort (23 of whom had DCM). Endomyocardial biopsies
were performed in 117 (10.5%) patients, of which 70 were reported
to be diagnostic. Seventy one (60.1%) patients were entered by cen-
tres from Italy (n ¼ 40, 34.2%) and a single centre in the Czech Re-
public (n ¼ 31, 26.5%). Endomyocardial biopsy was performed most
frequently in patients with RCM.
Medication
One thousand and twenty-six patients (92.0%) were receiving one
or more drugs for their cardiomyopathy. The breakdown of individ-
ual classes of drug by cardiomyopathy subtype is shown in Table 2.
The majority of patients with all types of cardiomyopathies were
receiving a beta-blocker. Angiotensin-converting enzyme (ACE) in-
hibitors, angiotensin receptor blockers (ARBs), and mineralocortic-
oid receptor antagonists were used in all four types of
cardiomyopathies, with the highest use of all three classes of drug
in patients with DCM. Oral anticoagulants were used in 283
(27.6% of those recorded) and in .50% of the patients with
RCM. Two hundred and thirteen patients (20.8%) with a history
of atrial fibrillation (AF) were receiving oral anticoagulants [133
(22.1%) with HCM; 66 (19.4%) with DCM; 3 (5.5%) with ARVC;
and 11 (40.74%) with RCM].
Pacemakers and internal cardioverter
defibrillators
Three hundred and sixteen patients (28.3%) received an implantable
cardioverter defibrillator (ICD). The proportion was highest in
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Table 2 Baseline characteristics for each cardiomyopathy subtype enrolled into the cardiomyopathy registry
HCM (n 5 681) DCM (n 5 346) RCM (n 5 29) ARVC (n 5 59) P-value
Age at enrolment,
mean+ SD; median (IQR)
53.4+15.88 52.6+14.65 60.5+17.14 46.4+13.57 0.0003
54 (42–65) 54 (44–64) 65 (52–74) 49 (33–56)
Age at diagnosis,
mean+ SD; median (IQR)
43.7+19.0 46.1+15.7 56.9+20.56 37.7+15.39 ,0.0001
45 (30–58) 46 (37–57) 64 (37–75) 39 (29–49)
Males, n (%) 404/681 (59.3) 243/346 (70.2) 14/29 (48.3) 35/59 (59.3) 0.0023
Family history of SCD, n (%) 171/655 (26.1) 52/318 (16.4) 3/27 (11.1) 20/56 (35.7) 0.0003
Familial disease, n (%) 303/569 (53.3) 90/275 (32.7) 7/23 (30.4) 23/45 (51.1) ,0.0001
NYHA
Class I 282/681 (41.4) 99/346 (28.6) 6/29 (20.7) 31/59 (52.5) ,0.0001
Class II 262/681 (38.5) 103/346 (29.8) 13/29 (44.8) 17/59 (28.8)
Class III 96/681 (14.1) 75/346 (21.7) 9/29 (31.0) 1/59 (1.7)
Class IV 9/681 (1.3) 38/346 (11) 0 (0) 0 (0)
Chest pain 206/681 (30.3) 51/346 (14.7) 4/29 (13.7) 11/59 (18.6) ,0.0001
Extreme lethargy 62/681 (9.1) 63/346 (18.2) 2/29 (6.9) 2/59 (3.4) ,0.0001
Palpitations 175/681 (25.7) 73/346 (21.1) 3/29 (10.3) 31/59 (52.5) ,0.0001
Vasovagal or non-cardiac syncope, n (%) 31/681 (4.6) 8 (2.3) 0 (0) 0 (0) 0.0039
Suspected arrhythmic/cardiogenic syncope, n (%) 82/681 (12.0) 38/346 (11.0) 2/29 (6.9) 17/59 (28.8)
Syncope of uncertain mechanism, n (%) 28/681 (4.1) 7/346 (2.0) 3/29 (10.3) 2/59 (3.4)
Procedures prior to enrolment
Septal myectomy, n (%) 31/681 (4.6) – – –
Alcohol septal ablation, n (%) 49/681 (7.2) – – –
AF ablation procedure, n (%) 17/24 (70.8) 8/19 (42.1) 0 (0) 2/6 (33.3) 0.0079
ICD primary prophylaxis 132/681 (19.4) 97/346 (28.0) 1/29 (3.5) 26/59 (44.1) ,0.0001
ICD secondary prophylaxis 21/681 (3.1) 30/346 (8.7) 1/29 (3.5) 8/59 (13.6)
Medications
Beta-blockers, n (%) 470/603 (77.9) 301/341 (88.3) 15/27 (55.6) 49/55 (89.1) ,0.0001
ACE-inhibitors, n (%) 100/603 (16.6) 249/341 (73.0) 6/27 (22.2) 14/55 (25.5) ,0.0001
Angiotensin II receptor blockers, n (%) 92/603 (15.3) 65/341 (19.1) 3/27 (11.1) 4/55 (7.3) 0.1010
Mineralocorticoid receptor antagonists, n (%) 78/603 (12.9) 173/341 (50.7) 11/27 (40.7) 6/55 (10.9) ,0.0001
Diuretics, n (%) 181/603 (30.0) 218/341 (63.6) 23/27 (85.2) 10/55 (18.2) ,0.0001
Antiplatelets, n (%) 148/601 (24.5) 71/340 (20.8) 7/27 (25.9) 12/55 (21.8) 0.5985
Oral anticoagulants, n (%) 160/601 (26.5) 100/340 (29.3) 16/27 (59.3) 7/55 (12.7) 0.0001
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic
cardiomyopathy; ICD, Implantable cardioverter defibrillator; NYHA, New York Heart Association; RCM, restrictive cardiomyopathy; SCD, sudden cardiac death.
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patients with ARVC (n ¼ 34, 57.6%) and lowest in those with RCM
(n ¼ 2, 6.9%). The majority of devices were for primary prophylaxis.
The highest proportion for secondary prophylaxis was observed in
patients with ARVC (n ¼ 8). The number of patients with a pace-
maker alone was 86 (8.0%). The commonest indication was for bra-
dyarrhythmia/conduction disease, followed by treatment for left
ventricular outflow tract gradient in patients with HCM. A total of
58 (5.2%) patients had a cardiac resynchronization therapy device
at enrolment.
Discussion
This is the first European registry for cardiomyopathy. As the centres
selected for the pilot phase were, by definition, specialized referral
units with a high volume of cases, the data reported are not neces-
sarily representative of the usual standard in different European na-
tions, but the registry does show that patients in such centres require
intensive investigation and access to specialized diagnostic tests. The
data also show that the utilization of drug and device therapy is con-
siderable for this selected group of patients.
General characteristics of the cohort
In accordance with published data, HCM was the most frequently
recorded cardiomyopathy, followed by DCM, ARVC, and RCM.2–9
Although rare, features consistent with LVNC were most commonly
reported in patients with DCM, consistent with previous studies
reporting a relatively high prevalence of LVNC in patients with systolic
LV failure and may represent the low specificity of current diagnostic
criteria.11
In the three most common cardiomyopathy subtypes, the major-
ity of patients were diagnosed before the age of 50 years, a trend
that was most striking for ARVC. Although the commonest reason
for diagnosis in the cohort as a whole was symptomatic presenta-
tion, diagnosis through screening accounted a relatively large pro-
portion (particularly for HCM and ARVC), illustrating the growing
importance of family evaluation—and by implication genetic coun-
selling and testing—in contemporary cardiomyopathy services.12–14
The age trend was reversed in patients with RCM, reflecting the
high proportion of patients in this group with transthyretin and light
chain amyloidosis, diseases that present in the later decades
of life.15,16
In all cardiomyopathy subtypes, there was an unequal sex distri-
bution, with a skew towards men for HCM, DCM, and ARVC and
towards women for RCM. The bias towards men has been observed
previously in HCM, DCM, and ARVC and is usually attributed to an
earlier onset of cardiac expression (or penetrance) in males when
compared with women, but the mechanism remains largely unex-
plained.17 It is possible that the modifier effects of sex hormones are
responsible, but other factors ranging from genetics to behavioural
patterns and social influences are likely to be equally if not more
important.
Familial disease
A major finding in this study was the large proportion of patients in
whom familial disease was reported. This is particularly striking given
that only 15% of the patients were diagnosed as the result of family
screening, illustrating the delay in referring individuals with a family
history for further evaluation. A more detailed analysis of the genetic
workup of patients in the registry will follow this report, but the
large proportion of patients undergoing genetic testing and the
high diagnostic yield show that, at least within specialist cardiomyop-
athy centres, genetic evaluation is firmly established as part of
routine practice and is very efficient in experienced hands.
Diagnostic workup
This pilot shows that in specialist centres, patients with cardiomyop-
athy are subjected to many non-invasive tests. This reflects the com-
plexity of diagnosis in some subtypes and the need for risk
assessment for disease-related complications such as atrial and ven-
tricular arrhythmia. The number of patients undergoing cardiac
magnetic resonance imaging was relatively high, particularly in
ARVC in which detection of subtle structural abnormalities in the
right and left ventricles is challenging with ultrasound imaging alone.
As there are no randomized, controlled data on the utility of en-
domyocardial biopsy, current ESC guidelines rely on consensus re-
commendations built around a set of clinical scenarios in which
endomyocardial biopsy has some potential to aid diagnosis.18 Of
these, only two relating to new-onset heart failure of ,2 weeks
duration are given class 1 status; all recommendations relating to
chronic presentations of cardiomyopathy are graded at intermedi-
ate levels. It is, therefore, of note that more than 1 in 10 of the pilot
registry population underwent a cardiac biopsy. The greatest use
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Cardiac investigations performed in individual cardiomyopathy subtypes
HCM (n 5 681) DCM (n 5 346) RCM (n 5 29) ARVC (n 5 59)
ECG, n (%) 650/681 (95.5) 345/346 (99.7) 29/29 (100) 59/59 (100)
Transthoracic echocardiography, n (%) 675/681 (99.1) 342/346 (98.8) 29/29 (100) 58/59 (98.3)
Cardiac MRI, n (%) 334/681 (49.0) 124/346 (35.8) 12/29 (41.4) 37/59 (62.7)
Ambulatory ECG monitoring, n (%) 541/681 (79.4) 153/346 (44.2) 10/29 (34.5) 49/59 (83.1)
Exercise test, n (%) 416/681 (61.1) 108/346 (31.2) 2/29 (6.90) 38/59 (64.4)
Endomyocardial biopsy, n (%) 15/676 (2.5) 71/346 (20.5) 17/29 (58.6) 14/58 (24.1)
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; RCM, restrictive
cardiomyopathy; MRI, magnetic resonance imaging.
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was in patients with RCM, reflecting the importance of infiltrative
disease in this cohort, and the least in individuals with HCM in
whom the current consensus is that it is of only limited use.9 A
cautionary note is that almost two-thirds of the biopsies were
reported from Italian centres and a single centre in the Czech
Republic. Future work in the long-term registry will explore the
Figure 3 (A) Distribution of age at diagnosis for each cardiomyopathy subtype by quartiles of age (years). (B) Box-plot with jittered distribution
of age at diagnosis for each cardiomyopathy subtype. ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy;
HCM, hypertrophic cardiomyopathy; RCM, restrictive cardiomyopathy.
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variance between referral centres and examine the clinical utility of
endomyocardial biopsy in patients with clinically suspected
myocarditis.
Medical therapy
Patients with cardiomyopathy often require drug therapy to
improve symptoms and prognosis. It is particularly striking in this
pilot that—irrespective of the underlying diagnosis—more than
90% of the patients were receiving one or more long-term medica-
tions. The most frequently used drugs across all cardiomyopathy
types were beta-blockers, reflecting current guidelines for the
management of cardiomyopathy.19 With respect to other drugs,
ACE inhibitors and ARBs were almost universal in patients
with DCM, but used much less frequently in other cardiomyopathy
types. The use of oral anticoagulants was high, with the greatest
use in RCM, probably reflecting the higher incidence of AF in this
group.
Implantable devices
More than a quarter of all patients had an ICD at enrolment into the
study. The proportions for HCM and DCM are broadly in line with
that reported in contemporary studies,20,21 except for ARVC in
which 60% had a device (predominantly for primary prophylaxis).22
This high rate of ICD implantation might reflect a bias towards pa-
tients with more severe disease in the registry, but the explanation
may be more complex and reflect the lack of clear guidelines on ICD
implantation in this disease. We hope this will be explored in future
substudies.
Value of registries
Compared with prospective cohort studies, registries have some
limitations with respect to detailed analyses of specific scientific
questions, but they are of great value in providing real-world data
on the course of disease and variations in treatment and outcomes.
One of the goals of the long-term cardiomyopathy registry is to
gather data on disparities in the delivery of care and so provide
the basis for a better understanding of the effectiveness of care in
referral and non-referral settings.
Limitations
The data collected in this pilot are confined to adult patients.
Paediatric registries in North America and Australia suggest that
there are important differences in the aetiology and natural history
of cardiomyopathy in children,23,24 and the long-term cardiomyop-
athy registry will prospectively collect data in the paediatric
population.
For the purposes of this registry, DCM was defined by dilatation
and impairment of systolic function of the left ventricle or both ven-
tricles, in the absence of coronary artery disease, valvular abnormal-
ities, or pericardial disease. Endomyocardial biopsy was not a
prerequisite for inclusion into the pilot, and so we are unable to
comment on the prevalence of inflammatory cardiomyopathy in
this cohort. Data on patients with biopsy-proven myocarditis will
be prospectively collected in the long-term registry.
The proportion of individuals with rare phenocopies is relatively
low in this pilot survey. This may reflect the true prevalence of these
disorders, but might also be explained by variation in the extent of
screening (clinical and genetic) for rarer diseases.
Conclusions
Acknowledging that this is only a snap shot of practice in specialized
centres, the characteristics of the patient population are in most re-
spects very similar to those reported in the literature from a variety
of clinical settings. It is clear from this pilot that services for patients
with cardiomyopathy are complex, requiring access to a large range
of invasive and non-invasive investigations and involvement of multi-
disciplinary teams with expertise in genetics, imaging, electrophysi-
ology, and heart failure management. Treatment regimens are
equally multifaceted and mean that patients are likely to need long-
term follow-up in close liaison with expert centres. Many findings—
for example, the very high use of ICDs in ARVC and the high yield
from genetic testing—will be examined in substudies from the pilot
and in the long-term registry that will also examine inflammatory
myocardial disease and younger cohorts.
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Pitié-Salpetriere—R. Cheikh Khelifa, E. Gandjbakhch, M. Komajda;
Germany: Schweinfurt: Leopoldina-Krankenhaus—A. Neugebauer,
B. Pfeiffer; Greece: Athens: Ippokrateion General Hospital—A. Ster-
iotis, K. Ritsatos, V. Vlagkouli; Italy: Bologna: Alma Mater—University
di Bologna—E. Biagini, N. Gentile, S. Longhi; Firenze: Università di
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